Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.

Grab's 62% rally in six months, rising GMV, fintech growth and bold AV bets fuel optimism despite premium valuation.

AXIS Capital gains from a well-performing specialty insurance, reinsurance, as well as the accident and health portfolio.

A Jefferies analyst thinks Wall Street is reading too much into strong early demand for the iPhone 17 — setting the stage for disappointment down the road.

Applied Materials Inc (NASDAQ:AMAT, ETR:AP2) shares slipped more than 3% in early trading on Friday after the maker of machinery used to manufacture semiconductors revealed in a regulatory filing that new US export restrictions to China would hurt its revenue. The company expects the decision will result in about $600 million of lost revenue in fiscal 2026, which runs through next October.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune (ALT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

AbbVie is outperforming expectations with strong commercial results, pipeline progress, and the legal win that secured Rinvoq's long-term market exclusivity. ABBV has raised the full-year revenue guidance by $1.5 billion since the start of the year, and I am raising my estimate range again to reflect the better-than-expected performance. The pipeline is delivering late-stage wins, notably with Rinvoq, Epkinly, and Qulipta.

ADI sees strong momentum in industrial and automotive growth, aiming to push margins past 70% in the coming quarters.

RAVE slips on flat fourth-quarter fiscal 2025 EPS and weak sales, but Pizza Inn's promotions and expansion show signs of underlying strength.

U.S. defence firm Northrop Grumman is testing higher calibre cannon bullets to shoot down drones at lower cost, based on feedback from Ukrainian soldiers who are increasingly facing swarms of high-flying unmanned aircraft, a top company executive told Reuters.

HIMS boosts predictable revenue and customer loyalty with a flexible, subscription-based model across key health categories.

Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.

GFI, GMAB and AEG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 3, 2025.

Unity Bancorp (UNTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Join over 85 top chefs at delicious Houston charity event aimed at raising funds to help our food & beverage community overcome crises Join over 85 top chefs at delicious Houston charity event aimed at raising funds to help our food & beverage community overcome crises

Award-Winning Overbed Design Expands to Behavioral Health & General Use Models & More Sizes Award-Winning Overbed Design Expands to Behavioral Health & General Use Models & More Sizes

Even Apple Inc (NASDAQ:AAPL, ETR:APC) is not immune to scepticism. On Friday, Jefferies cut its rating on the iPhone maker to “underperform”, warning that investors are getting carried away with how quickly consumers will trade up their handsets.

New data provided to CNBC from Motor Intelligence shows U.S. sales of electric vehicles topped 1 million units through the first nine months of the year. EVs also set a new quarterly record of more than 438,000 units sold during the third quarter — achieving market share of 10.5% for the period.

Berkshire Hathaway votes to separate chairman and CEO roles, paving way for Abel to succeed Buffett at year-end

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.